Investment, Funding & Disinvestments
-
Boehringer Ingelheim inks USD500M immunology deal with Sitryx to target autoimmune disease
Sitryx stands to receive development, regulatory, and commercialization milestone payments exceeding USD 500 million, alongside tiered royalties on future sales if any drug from the partnership reaches the market.
-
CordenPharma Colorado to scale peptide development at new LEED Gold facility
The LEED Gold-certified facility features flexible laboratory configurations and advanced mechanical and utility systems, enabling researchers to conduct intricate scientific research.
-
Nanologica acquires Ardena’s Syntagon Facility to expand API manufacturing
The site will continue operating as a subsidiary under the Syntagon name, maintaining its established brand presence in the pharmaceutical manufacturing sector.
-
BioDuro expands API production to Taiwan through new joint venture with Cenra
The venture aims to deliver comprehensive active pharmaceutical ingredient (API) services, covering everything from initial development stages through full-scale commercial production.
-
Roche commits USD484M to boost South Korea’s biopharma ecosystem
The company formalized its commitment with South Korea’s Ministry of Health and Welfare to enhance the bio-healthcare industry by supporting international clinical trials and advancing research for innovative medicines.
-
Sanofi acquires global rights to Sino Biopharmaceutical’s Anxu in USD1.53B deal
The agreement includes a USD135 million upfront payment to Sino Biopharmaceutical for worldwide rights, with up to USD1.39 billion in potential milestone payments based on development, regulatory approvals, and sales.
-
Fidson Healthcare wins USD6.2 billion deal to boost local ARV production
This strategic approach aligns with President Bola Tinubu’s broader vision to unlock the healthcare value chain by empowering local pharmaceutical industries.
-
Teva secures USD400M from Blackstone to advance bowel disease drug development
The Israeli pharmaceutical company will receive the funding over four years to support ongoing trials of the anti-TL1A antibody, which Teva is co-developing with Sanofi.
-
UCB secures USD1.1 B global rights for Antengene’s next-generation autoimmune therapy
ATG-201 is designed as a bispecific molecule that binds to both CD3 on T cells and CD19 on B cells, effectively recruiting the body’s own immune system to destroy disease-causing B cells.
-
PharmaEssentia invests USD46M in Puerto Rico’s manufacturing facility
The new manufacturing hub represents a core strategic priority for PharmaEssentia as the company works to strengthen its supply chain, increase production flexibility, and diversify its geographic footprint.